Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study

Marta Roldo; Eugen Barbu; James Brown; David Laight; J. Smart; John Tsibouklis

doi:10.1002/jbm.a.30810

Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study

Marta Roldo, Eugen Barbu, James Brown, David Laight, J. Smart, John Tsibouklis

Research output: Contribution to journal › Article › peer-review

Abstract

Radiolabeled congeners of a series of azopolymers have been synthesized and characterized. The in vivo (rat) gastrointestinal transit profile of millimeter-sized particles of these azopolymers has been determined and used to facilitate the selection of a candidate material for therapeutic applications. The efficacy of the selected material as a protective coating for the colonic mucosa has been tested in a hapten-reactivated, in vivo model of inflammatory bowel disease: 7 days after reactivation of the condition, the myeloperoxidase activity of animals that had received doses of the selected azopolymer was determined to be at the same level as that of healthy animals or that of the negative control group, highlighting the therapeutic promise of this material.

Original language	English
Pages (from-to)	706-715
Number of pages	10
Journal	Journal of Biomedical Materials Research Part A
Volume	79A
Issue number	3
DOIs	https://doi.org/10.1002/jbm.a.30810
Publication status	Published - 2006

Access to Document

10.1002/jbm.a.30810

Cite this

@article{e96fdb60868244e0878acf0ccfe4b6ac,

title = "Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study",

abstract = "Radiolabeled congeners of a series of azopolymers have been synthesized and characterized. The in vivo (rat) gastrointestinal transit profile of millimeter-sized particles of these azopolymers has been determined and used to facilitate the selection of a candidate material for therapeutic applications. The efficacy of the selected material as a protective coating for the colonic mucosa has been tested in a hapten-reactivated, in vivo model of inflammatory bowel disease: 7 days after reactivation of the condition, the myeloperoxidase activity of animals that had received doses of the selected azopolymer was determined to be at the same level as that of healthy animals or that of the negative control group, highlighting the therapeutic promise of this material.",

author = "Marta Roldo and Eugen Barbu and James Brown and David Laight and J. Smart and John Tsibouklis",

year = "2006",

doi = "10.1002/jbm.a.30810",

language = "English",

volume = "79A",

pages = "706--715",

journal = "Journal of Biomedical Materials Research Part A",

issn = "1549-3296",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study

AU - Roldo, Marta

AU - Barbu, Eugen

AU - Brown, James

AU - Laight, David

AU - Smart, J.

AU - Tsibouklis, John

PY - 2006

Y1 - 2006

N2 - Radiolabeled congeners of a series of azopolymers have been synthesized and characterized. The in vivo (rat) gastrointestinal transit profile of millimeter-sized particles of these azopolymers has been determined and used to facilitate the selection of a candidate material for therapeutic applications. The efficacy of the selected material as a protective coating for the colonic mucosa has been tested in a hapten-reactivated, in vivo model of inflammatory bowel disease: 7 days after reactivation of the condition, the myeloperoxidase activity of animals that had received doses of the selected azopolymer was determined to be at the same level as that of healthy animals or that of the negative control group, highlighting the therapeutic promise of this material.

AB - Radiolabeled congeners of a series of azopolymers have been synthesized and characterized. The in vivo (rat) gastrointestinal transit profile of millimeter-sized particles of these azopolymers has been determined and used to facilitate the selection of a candidate material for therapeutic applications. The efficacy of the selected material as a protective coating for the colonic mucosa has been tested in a hapten-reactivated, in vivo model of inflammatory bowel disease: 7 days after reactivation of the condition, the myeloperoxidase activity of animals that had received doses of the selected azopolymer was determined to be at the same level as that of healthy animals or that of the negative control group, highlighting the therapeutic promise of this material.

U2 - 10.1002/jbm.a.30810

DO - 10.1002/jbm.a.30810

M3 - Article

SN - 1549-3296

VL - 79A

SP - 706

EP - 715

JO - Journal of Biomedical Materials Research Part A

JF - Journal of Biomedical Materials Research Part A

IS - 3

ER -

Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study

Abstract

Access to Document

Fingerprint

Cite this